deltatrials
Terminated PHASE2 NCT03272217

Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer

A Phase II Trial of Atezolizumab and Bevacizumab in Cisplatin-ineligible Patients With Advanced/Unresectable Urothelial Cancer

Sponsor: Arjun Balar, MD

Conditions Urothelial Carcinoma
Interventions Atezolizumab Bevacizumab
Updated 23 times since 2017 Last updated: Dec 12, 2024 Started: Sep 13, 2017 Primary completion: May 27, 2021 Completion: Mar 17, 2022

This PHASE2 trial investigates Urothelial Carcinoma and is currently terminated or withdrawn. Arjun Balar, MD leads this study, which shows 23 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Oct 2017 – ~Nov 2017 · 31 days · monthly snapshot~Nov 2017 – ~Mar 2018 · 4 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Mar 2019 · 7 months · monthly snapshot~Mar 2019 – ~Aug 2019 · 5 months · monthly snapshot~Aug 2019 – ~Oct 2019 · 2 months · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Mar 2020 · 4 months · monthly snapshot~Mar 2020 – ~Aug 2020 · 5 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~May 2021 · 3 months · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~Feb 2022 · 5 months · monthly snapshot~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshot~Mar 2022 – ~Sep 2022 · 6 months · monthly snapshot~Sep 2022 – ~Jan 2023 · 4 months · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshot~Feb 2025 – present · 14 months · monthly snapshot

Change History

23 versions recorded

  1. Feb 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2024 — Feb 2025 [monthly]

    Terminated PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  4. Jan 2023 — Jul 2024 [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

  5. Sep 2022 — Jan 2023 [monthly]

    Active Not Recruiting PHASE2

▶ Show 18 earlier versions

  1. Mar 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE2

  2. Feb 2022 — Mar 2022 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2021 — Feb 2022 [monthly]

    Active Not Recruiting PHASE2

  4. May 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  5. Feb 2021 — May 2021 [monthly]

    Recruiting PHASE2

  6. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE2

  7. Aug 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  8. Mar 2020 — Aug 2020 [monthly]

    Recruiting PHASE2

  9. Nov 2019 — Mar 2020 [monthly]

    Recruiting PHASE2

  10. Oct 2019 — Nov 2019 [monthly]

    Recruiting PHASE2

  11. Aug 2019 — Oct 2019 [monthly]

    Recruiting PHASE2

    Status: Active Not Recruiting → Recruiting

  12. Mar 2019 — Aug 2019 [monthly]

    Active Not Recruiting PHASE2

  13. Aug 2018 — Mar 2019 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  14. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE2

  15. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE2

  16. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

  17. Nov 2017 — Mar 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  18. Oct 2017 — Nov 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Sep 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Arjun Balar, MD
  • Hoosier Cancer Research Network
  • Roche-Genentech
Data source: Hoosier Cancer Research Network

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations